NASH cirrhosis

View All

NASH Emerging therapies
NASH Emerging Therapies

Earlier in our article, we discussed how mostly off-label therapies so far dominate the NASH therapeutics market. So, let us dig deeper into it and find out what can we expect in the coming years in term of NASH treatments. As we know, there is no approved therapy available for NASH, and many Doctors rely on off-la...

Find More

NASH therapies
Off-label therapies dominate NASH Market Share

NASH market share of off label therapies, it will keep on experiencing a steady growth until a standard approved therapy enters the NASH treatment market. Non-alcoholic fatty liver disease (NAFLD), is the most common group of conditions in which there is an excess fat accumulation in the liver in people who i...

Find More

Delveinsight
Meeting the Unmet: Nonalcoholic Steatohepatitis (NASH)

NASH is defined as the most common form of Nonalcoholic fatty liver disease (NAFLD). The disease is characterized by a spectrum of symptoms including simple steatosis, increased levels of fibrosis, and cirrhosis of the liver. NASH can also result in advanced fibrosis, NASH cirrhosis, and NASH Decompensated Cirrhosi...

Find More